Article
Hematology
Viviane Gournay, Nicolas Vallet, Vivien Peux, Kristi Vera, Jennifer Bordenave, Marion Lambert, Aurelien Corneau, David Michonneau, Regis Peffault de Latour, Sophie Caillat-Zucman, Gerard Socie, Mathieu F. Chevalier
Summary: This study comprehensively characterized the immune cells in patients after allo-HSCT using mass cytometry, and identified certain features associated with relapse of AML, providing new insights for restoring anti-AML immunity.
Editorial Material
Hematology
Melody Smith, Kate A. Markey
Summary: This study found that pediatric allo-HSCT patients with high microbial diversity prior to transplantation had longer overall survival and a lower incidence of acute GVHD. This is consistent with previous findings in adult allo-HSCT recipients. However, a key difference in this study is that the post-neutrophil engraftment microbiome was not associated with outcome, unlike in adults.
Review
Immunology
Franziska Karl, Michael Hudecek, Friederike Berberich-Siebelt, Andreas Mackensen, Dimitrios Mougiakakos
Summary: Allogeneic-hematopoietic stem cell transplantation is the only curative treatment for various hematological malignancies, but Graft-versus-Host-Disease often occurring with Graft-versus-Tumor effect poses a challenge for therapeutic efficacy. Immuno-metabolic interventions are being explored as a promising option to alleviate GvHD without compromising GvT activity. The interconnection between immunological and metabolic pathways is crucial in understanding and addressing the immuno-metabolic signature of GvHD-driving T-cells.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Immunology
Shideh Namazi Bayegi, Amir Ali Hamidieh, Maryam Behfar, Mahmood Bozorgmehr, Amene Saghazadeh, Nader Tajik, Ali-Akbar Delbandi, Farzaneh Tofighi Zavareh, Samaneh Delavari, Mehdi Shekarabi, Nima Rezaei
Summary: Reconstitution of T-cell subsets after allo-HSCT is critical for pathogen protection and preventing GvHD. CD4 and CD8 T-cells were higher 12 months after the transplant but still lower than in healthy controls and pre-transplant. Acute GvHD was associated with an increase in TEMRA cells in CD4 T-cells, while chronic GvHD was associated with a decrease in Th1 cells in CD4 T-cells and effector memory cells in CD8 T-cells.
IMMUNOLOGY LETTERS
(2023)
Editorial Material
Hematology
Roni Shouval, Robert J. Soiffer
Summary: The study in this issue of Blood explores the potential use of a knowledge bank to guide decision making on whether AML patients aged 18 to 59 should undergo allogeneic HSCT in first complete remission or at a later stage.
Review
Medicine, General & Internal
Christos Demosthenous, Ioanna Sakellari, Vassiliki Douka, Penelope Georgia Papayanni, Achilles Anagnostopoulos, Eleni Gavriilaki
Summary: MDSCs play a role in suppressing GVHD toxicity after allo-HCT, but their impact on the GVL effect is not fully defined. Studying MDSC metabolism and inflammasome signaling pathways may help elucidate their function in GVHD pathogenesis.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Multidisciplinary Sciences
Mahinbanu Mammadli, Weishan Huang, Rebecca Harris, Hui Xiong, Samuel Weeks, Adriana May, Teresa Gentile, Jessica Henty-Ridilla, Adam T. Waickman, Avery August, Alaji Bah, Mobin Karimi
Summary: Inhibiting SLP76:ITK interaction may separate GVHD from GVL effects, providing a potential therapeutic strategy for allo-HSCT treatment.
Article
Cell Biology
Xiaoqing Li, Yixue Li, Qinru Yu, Lin Xu, Shan Fu, Cong Wei, Limengmeng Wang, Yi Luo, Jimin Shi, Pengxu Qian, He Huang, Yu Lin
Summary: mTOR signaling regulates MDSCs' generation via the STAT3-C/EBP beta pathway. Infusion of mTOR(KO) PMN-MDSCs shows potential in preventing and treating aGVHD by alleviating cytokine storm and promoting the recovery of PMN-MDSCs.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Oncology
Annika M. Kisch, Karin Bergkvist, Anette Alvariza, Kristofer Arestedt, Jeanette Winterling
Summary: The study aimed to investigate family caregivers' support needs before allo-HSCT, how these needs change over time, and their relationship with demographic factors and caregiver outcomes. The findings suggest that high support needs prior to transplantation are often linked to worse caregiver outcomes, and most support needs do not decrease over time. This highlights the importance of paying more attention to the needs of family caregivers.
SUPPORTIVE CARE IN CANCER
(2021)
Article
Oncology
Mahinbanu Mammadli, Rebecca Harris, Sara Mahmudlu, Anjali Verma, Adriana May, Rohan Dhawan, Adam T. Waickman, Jyoti Misra Sen, Avery August, Mobin Karimi
Summary: This study demonstrated the significant role of Wnt/beta-catenin in T cell-mediated GVHD after allogeneic transplantation, suggesting beta-catenin as a potential druggable target to reduce GVHD while preserving beneficial GVL effects. The findings also revealed changes in gene expression related to immune response and GVHD pathophysiology, shedding light on the uncoupling of GVHD from GVL effects.
Article
Hematology
Mikhail Drokov, Galina Yatsyk, Anna Kireeva, Olga Pirikova, Darya Dubnyak, Larisa Kuzmina, Vera Vasilyeva, Natalia Popova, Olga Starikova, Elena Parovichnikova, Valeriy Savchenko
Summary: Bowel wall thickness measured by transabdominal ultrasonography can predict the steroid-refractoriness of aGVHD with gut involvement after allo-HSCT.
INTERNATIONAL JOURNAL OF HEMATOLOGY
(2022)
Article
Multidisciplinary Sciences
Jinhua Ren, QiaoXian Lin, Qi Chen, Jingjing Xu, Dabin Chen, Renli Chen, Kangni Lin, Haojie Zhu, Chenjing Ye, Xiaofeng Luo, Shaozhen Chen, Hui Kong, Qiong Lin, Nan Li, Xu Lin, Zhizhe Chen, Jianda Hu, Ting Yang
Summary: Adoptive transfer of HBV immunity was investigated in 112 patients without HBsAb at the time of their first allo-HSCT. After allo-HSCT, HBV-DNA and HBsAg cleared in HBsAg+ patients, while all HBsAg- patients acquired HBsAb immediately. However, HBsAb subsequently declined, with 58.2% of patients losing HBsAb during follow-up. Multivariate analysis suggested that lack of CMV clearance, aGVHD, and no HBsAb loss were independent risk factors for overall survival. Overall, adoptive immune transfer provides anti-HBV protection, and HBsAb loss after allo-HSCT predicts better survival.
Article
Oncology
RuiHao Huang, XiaoQi Wang, Xi Zhang
Summary: With the rapid development of therapies, hemopoietic stem cell transplantation (HSCT) and chimeric antigen receptor T (CAR-T) cell therapy have emerged as promising treatments for hematological malignancies. However, disease relapse, complications, and side effects continue to pose challenges. This review aims to explore ways to maximize the benefits of each therapy and improve patient prognosis.
Article
Virology
Hanying Liang, Jintao Xia, Runan Zhang, Bing Yang, Jian Wu, Genyong Gui, Yaping Huang, Xiaoming Chen, Rong Yang, Huiqi Wang, Shengnan Gong, Jun Fan
Summary: HCMV infection indicators for monitoring reactivation in transplant recipients have varying values, and further research is needed on the use of IFN-gamma SFCs counts for evaluating the risk of HCMV reactivation.
JOURNAL OF MEDICAL VIROLOGY
(2021)
Review
Immunology
Yu-Qian Sun, Rui Ma, Xiao-Jun Huang
Summary: This article summarizes recent advances in managing cytomegalovirus (CMV) infection post allogeneic hematopoietic stem cell transplantation (allo-HSCT), including diagnosis, prophylaxis, and treatment. The focus is on approaches that have optimized or might optimize the management of CMV infection after allo-HSCT.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY
(2023)
